Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months

International Journal of Geriatric Psychiatry

Volumn 23, Issue 2, 2008, Pages 207-214

  Rockwood, Kenneth ^a   Dai, Dingwei ^a   Mitnitski, Arnold ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Effect sizes; Galantamine; Long term treatment; Responders

Indexed keywords

GALANTAMINE; PLACEBO;

AGED; AGGRESSIVENESS; AGITATION; ALZHEIMER DISEASE; ARTICLE; CALCULATION; CANADA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CLUSTER ANALYSIS; COGNITION; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEPRESSION; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FALLING; FEMALE; HUMAN; INJURY; INSOMNIA; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATHOLOGIC FRACTURE; PNEUMONIA; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; URINARY TRACT INFECTION; URINE INCONTINENCE;

AGED; ALZHEIMER DISEASE; CANADA; CHOLINESTERASE INHIBITORS; COGNITION; DISEASE PROGRESSION; EUROPE; FEMALE; FOLLOW-UP STUDIES; GALANTAMINE; HUMANS; LOGISTIC MODELS; MALE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 39749116926     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1864     Document Type: Article

References (33)

1. Aerssens J, Raeymaekers P, Lilienfeld S, et al. 2001. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12: 69-77.
2. Behl P, Lanctôt KL, Streiner DL, et al. 2006. Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the Sunnybrook dementia cohort. Curr Alzheimer Res 3: 147-156.
3. Bishop CM. 1995. Neural Networks for Pattern Recognition. Oxford University Press: Oxford.
4. Birks J. 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1: CD005593.
5. Bowler JV, Munoz DG, Merskey H, et al. 1998. Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease; J Neurol Neurosurg Psychiatry 64: 18-24.
6. Bullock R, Dengiz A. 2005. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 59: 817-822.
7. Chan PL, Holford NH. 2001. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 41: 625-659.
8. Courtney C, Farrell D, Gray R, et al. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105-2115.
9. Cummings JL. 2006. What we can learn from open-label extensions of randomized clinical trials. Arch Neurol 63: 18-19.
10. Doody RS, Geldmacher DS, Gordon B, et al. 2001. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58: 427-433.
11. Erkinjuntti T, Kurz A, Small GW, et al. 2003. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 25: 1765-1782.
12. Farlow MR, Lilly ML. 2005. ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr 5: 3.
13. Feldman HH, Van Baelen B, Kavanagh SM, et al. 2005. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 19: 29-36.
14. Holmes C, Lovestone S. 2003. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing 32: 200-204.
15. Johnsen S, Hughes S, Bullock R, Hindmarch I. 2003. Prediction of the rate of decline in cognitive function in Alzheimer's disease: a model based on simple demographic data and widely used rating scales. Dement Geriatr Cogn Disord 16: 276-282.
16. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. 2005. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331: 321-327.
17. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. 2004. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 12: 473-482.
18. MacKay D. 2003. Information Theory, Clustering and Algorithms. Oxford University Press: Oxford.
19. Mitnitski A, Graham J, Rockwood K. 1999. Modeling decline in Alzheimer's disease. Int Psychogeriatr 11: 211-216.
20. Morris JC, Edland S, Clark C, et al. 1993. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 43: 2457-2465.
21. Perrault A, Wolfson C, Egan M, et al. 2002. Prognostic factors for functional independence in older adults with mild dementia: results from the Canadian study of health and aging. Alzheimer Dis Assoc Disord 16: 239-247.
22. Pirttilä T, Wilcock G, Truyen L, Damaraju CV. 2004. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 11: 734-741.
23. Raskind MA, Peskind ER, Truyen L, et al. 2004. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 61: 252-256.
24. Ritchie CW, Ames D, Clayton T, Lai R. 2004. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 12: 358-369.
25. Rockwood K. 2004. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 677-685 (erratum in 75: 1086).
26. Rockwood K, Mintzer J, Truyen L, et al. 2001. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 71: 589-595.
27. Rockwood K, Black SE, Robillard A, Lussier I. 2004. Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey. Int J Geriatr Psychiatry 19: 954-960.
28. Schneider L. 2004. AD 2000:donepezil in Alzheimer's disease. Lancet 363: 2100-2101.
29. Stern RG. Mohs RC, Davidson M, et al. 1994. A longitudinal study of Alzheimer's disease. Am J Psychiatr 151: 390-396.
30. Suh GH, Ju YS, Yeon BK, Shah A. 2004. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry 19: 817-824.
31. van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. 2006. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 14: 428-437.
32. Wilcock GK, Lilienfeld S, Gaens E. 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321: 1445-1449 (erratum in: BMJ 322: 405).
33. Zar JH. 1984. Biostatistical Analysis, 2nd edn. Prentice Hall: Engelwood Cliffs, NJ; 312-315.